Please assess the completion status of the following clinical trial:

Trial Title: Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed Written Informed Consent.~2. Target Population~   a)18 to 65 years b)Newly diagnosed (≤ 3 months) Philadelphia chromosome positive chronic CP-CML c)Major BCR-ABL transcripts d)Not previously treated for CML except with hydroxyurea or anagrelide e)ECOG Performance Status≤ 2 f)Adequate Organ Function. i)Total bilirubin\< 2.0 times the institutional Upper Limit of Normal ii)Hepatic enzymes(AST, ALT )≤ 2.5 ULN iii)Serum Na, K+, Mg2+ and Ca2+ \> Lower Limit of Normal (LLN) or supplemented iv)Serum Creatinine\< 1.5 ULN g)Women of childbearing potential (WOCBP) must be using an adequate method of contraception.~3. Free subject, without guardianship nor subordination,~4. Health insurance coverage. -~Exclusion Criteria:~1. Patients with BCR-ABL other than M-BCR-ABL, Philadelphia negative CML.~2. Patients previously treated with Tyrosine Kinase Inhibitors (TKIs).~3. Medical history and concurrent diseases :~   1. Hypersensitivity to any of the excipients of dasatinib~  2. Prior treatment with Interferon-α, contraindication to interferon-α, hypersensitivity to any of the excipients of PegIFNα2b,~  3. Concomitant immunosuppressive treatment or corticosteroids,~  4. Preexisting thyroid disease unless it is controlled with conventional treatment, Auto-immune thyroiditis,~  5. Autoimmune disorder, Chronic liver disease,~  6. Prior or ongoing severe psychiatric disease,~  7. Epilepsy or compromised central nervous system(CNS) function,~  8. HIV positivity, chronic hepatitis B or C,~  9. Uncontrolled or significant cardio vascular or pulmonary disease,~   i)Uncontrolled angina, myocardial infarction or congestive heart failure within 6 months, ii)Echocardiography with LVF \< 45% or LLN, peak velocity of tricuspid regurgitant flow \> 2,8 m/s iii)Pulmonary arterial hypertension (PAH), iv)Any history of clinically significant ventricular or supraventricular arrhythmias, v)Diagnosed congenital long QT syndrome, vi)Prolonged QTc interval \> 450 msec (Fredericia) on 3 pre-entry electrocardiogram, vii)Subjects with hypokalemia or hypomagnesemia if it cannot be corrected, j)Other malignant disease during the last 5 years prior to the inclusion except basal cell carcinoma of the skin or carcinoma in situ of the cervix, k)History of significant bleeding disorder unrelated to CML, including: i)Diagnosed congenital bleeding disorders (e.g. von Willebrand's disease), ii)Ongoing or recent (≤ 3 months) significant gastrointestinal bleeding. l)Another severe or life -threatening medical disease.~4. Women who are pregnant or breastfeeding, WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 4 weeks after the last dose of study drug.~5. Prohibited treatments and/or therapies:~   1. strong inhibitors of the CYP3A4,~  2. category I drugs that are generally accepted to have a risk of causing Torsades de Pointes, Patients must discontinue the drug minimum 7 days prior to starting dasatinib.~6. History /any condition for poor compliance to the treatment.~7. Inability to freely provide consent through judiciary or administrative condition.~8. Ongoing participation to another study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dasatinib (Type: EXPERIMENTAL): Dasatinib,Bristol Myers Squibb
- Peg-Interferon alpha2b (Type: EXPERIMENTAL): Peg-Interferon alpha2b (Peg-IFN α2b), Merck

Based on this trial design, predict the completion outcome and termination type (if applicable).